相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)
Steven P. Marso et al.
AMERICAN JOURNAL OF CARDIOLOGY (2018)
Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials
Xiao-dong Zhuang et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease Results of the LEADER Trial
Subodh Verma et al.
CIRCULATION (2018)
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
Liana K. Billings et al.
DIABETES CARE (2018)
Impact of Intensive Lifestyle Intervention on Disability-Free Life Expectancy: The Look AHEAD Study
Edward W. Gregg et al.
DIABETES CARE (2018)
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
Bernard Zinman et al.
DIABETES CARE (2018)
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride
Sven Kohler et al.
DIABETES CARE (2018)
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
Richard E. Pratley et al.
DIABETES OBESITY & METABOLISM (2018)
Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D)
Patrick B. Ryan et al.
DIABETES OBESITY & METABOLISM (2018)
Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
Ronnie Aronson et al.
DIABETES OBESITY & METABOLISM (2018)
Biosimilar vs originator insulins: Systematic review and meta-analysis
Tomohide Yamada et al.
DIABETES OBESITY & METABOLISM (2018)
Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study
Cristian Guja et al.
DIABETES OBESITY & METABOLISM (2018)
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
Paola Fioretto et al.
DIABETES OBESITY & METABOLISM (2018)
Metformin in cancer
Ritwika Mallik et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?
Riccardo C. Bonadonna et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
HbA1c measurement in Germany: Is the quality sufficient for follow-up and diagnosis?
Lutz Heinemann et al.
DIABETOLOGIE UND STOFFWECHSEL (2018)
A randomized, open-label, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin u-100 versus concentrated lispro insulin u-200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence
Sandro Gentile et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis
Sean L. Zheng et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
Helena W. Rodbard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
Michael E. J. Lean et al.
LANCET (2018)
Does lower limb amputation concern all SGLT2 inhibitors?
Andre J. Scheen
NATURE REVIEWS ENDOCRINOLOGY (2018)
被撤回的出版物: Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality (Retracted article. See vol. 382, pg. 786, 2020)
J. R. Banegas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
Devin Abrahami et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
Devin Abrahami et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments
W. Ryan Powell et al.
DIABETES THERAPY (2018)
Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments
W. Ryan Powell et al.
DIABETES THERAPY (2018)
DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
Thomas R. Pieber et al.
DIABETOLOGIA (2018)
Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta-analysis of long-term randomized controlled trials
Kang Chen et al.
DIABETES OBESITY & METABOLISM (2018)
Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes
Robert Ritzel et al.
DIABETES OBESITY & METABOLISM (2018)
Identification of barriers to insulin therapy and approaches to overcoming them
David Russell-Jones et al.
DIABETES OBESITY & METABOLISM (2018)
Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review
Kamlesh Khunti et al.
DIABETES OBESITY & METABOLISM (2018)
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study
Frederik Persson et al.
DIABETES OBESITY & METABOLISM (2018)
Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes
Ivan Tkac et al.
DIABETES CARE (2017)
Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data
Steve Bain et al.
DIABETES OBESITY & METABOLISM (2017)
Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients
Olga Montvida et al.
DIABETES OBESITY & METABOLISM (2017)
Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review
Shishi Xu et al.
POSTGRADUATE MEDICINE (2017)
Cardiovascular safety of incretin-based therapy for type 2 diabetes: A meta-analysis of randomized trials
Ahmed N. Mahmoud et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database
Konstantinos A. Toulis et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients
Fei Wang et al.
MEDICINE (2017)
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor
Michael Fralick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F. E. Mann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Objectively Assessed Physical Activity and Weight Loss Maintenance among Individuals Enrolled in a Lifestyle Intervention
Jessica L. Unick et al.
OBESITY (2017)
Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis
Wen-Qin Guo et al.
VALUE IN HEALTH (2017)
Women and substance use: a qualitative study on sexual and reproductive health of women who use drugs in Delhi, India
Vartika Sharma et al.
BMJ OPEN (2017)
Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis
Jiali Liu et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis
Jiali Liu et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
David Z. I. Cherney et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
Ip Tim Lau et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2017)
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy
Philip D. Home et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials
Ilaria Dicembrini et al.
ACTA DIABETOLOGICA (2017)
Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study
Anna But et al.
DIABETOLOGIA (2017)
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials
Matteo Monami et al.
DIABETES OBESITY & METABOLISM (2017)
Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Simon J. Griffin et al.
DIABETOLOGIA (2017)
Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials
Matteo Monami et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
Gian Paolo Fadini et al.
DIABETOLOGIA (2017)
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
Mikhail Kosiborod et al.
CIRCULATION (2017)
Perioperative management of diabetic patients undergoing elective procedures. Part 2
R. Landgraf et al.
DIABETOLOGE (2017)
Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial
Keith Bowering et al.
DIABETES CARE (2017)
Efficacy of the Telemedical Lifestyle intervention Program TeLiPro in Advanced Stages of Type 2 Diabetes: A Randomized Controlled Trial
Kerstin Kempf et al.
DIABETES CARE (2017)
Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials
Bo Ahren et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetese
Thomas Nystrom et al.
DIABETES OBESITY & METABOLISM (2017)
Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies
Laurent Azoulay et al.
DIABETES CARE (2017)
Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Maria Ida Maiorino et al.
DIABETES CARE (2017)
Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia
Thomas Nystrom et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis
Ruijuan Wang et al.
ATHEROSCLEROSIS (2016)
Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
Keith C. Ferdinand et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
Christian Sonesson et al.
CARDIOVASCULAR DIABETOLOGY (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Naveed Sattar et al.
DIABETOLOGIA (2016)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano et al.
EUROPEAN HEART JOURNAL (2016)
Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes A Meta-analysis
Suetonia C. Palmer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
A Multicenter Observational Study of Incretin-based Drugs and Heart Failure
Kristian B. Filion et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
Ling Li et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Correction: The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials
Dimitris Varvaki Rados et al.
PLOS MEDICINE (2016)
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
Ling Li et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
Laurent Azoulay et al.
JAMA INTERNAL MEDICINE (2016)
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
Jason H. Y. Wu et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Heidi Storgaard et al.
PLOS ONE (2016)
Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies
Helle Linnebjerg et al.
DIABETES CARE (2015)
Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus (R)) in patients with type 2 diabetes who were insulin-naive or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2015)
Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart
T. Heise et al.
DIABETES OBESITY & METABOLISM (2015)
Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial
A. Ahmann et al.
DIABETES OBESITY & METABOLISM (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mortality risk among sulfonylureas: a systematic review and network meta-analysis
Scot H. Simpson et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1 324 515 patients from observational studies
T. Wang et al.
DIABETES OBESITY & METABOLISM (2015)
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
Michaela Diamant et al.
DIABETES CARE (2014)
Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
Rena Wing et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
K. G. M. M. Alberti et al.
CIRCULATION (2009)
分享论文
